Value of Immunohistochemistry for Somatostatin Receptor Subtype sst2A in Cancer Tissues
- 1 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in The American Journal of Surgical Pathology
- Vol. 29 (12) , 1642-1651
- https://doi.org/10.1097/01.pas.0000174013.14569.90
Abstract
The somatostatin receptor sst2A is highly expressed at the cellular surface of neuroendocrine and other human tumor cells, allowing somatostatin receptor-targeted scintigraphic tumor imaging and tumor therapy. In vitro information on tumoral somatostatin receptor expression is provided mainly by receptor autoradiography, based on binding of radiolabeled somatostatin analogs to tumoral somatostatin receptors. Recent availability of anti-sst2A antibodies opens the possibility of sst2A assessment in human tumors with immunohistochemistry. The aim of the present study was to evaluate the usefulness of several commercial anti-sst2A antibodies for this purpose in comparison with the extensively characterized antibody R2-88 and with receptor autoradiography. sst2A immunohistochemistry was performed in 64 formalin-fixed tumors known to frequently express sst2A (pancreatic, gastrointestinal, pulmonary neuroendocrine tumors, breast carcinomas, meningiomas, pituitary adenomas, neuroblastomas, medulloblastomas, pheochromocytomas, and paragangliomas); receptor autoradiography could be performed simultaneously in 37 of these cases. The commercial antibody SS-800 clearly identified sst2A and correlated excellently with R2-88: compared with R2-88, SS-800 immunohistochemistry generally yielded the same tissular and subcellular staining distribution. Results of R2-88 and SS-800 immunohistochemistry correlated excellently with those obtained with receptor autoradiography; compared with receptor autoradiography, immunohistochemistry with both R2-88 and SS-800 resulted in a slightly lower tumoral sst2A incidence, but a higher resolution, with frequent identification of heterogeneous sst2A distribution at high magnification. Finally, not only membranous, but also cytoplasmic, sst2A immunostaining was simultaneously observed with both antibodies in some tumors. In conclusion, the commercially available SS-800 antibody promises to be useful for the routine immunohistochemical assessment of sst2A in formalin-fixed human tumors.Keywords
This publication has 24 references indexed in Scilit:
- Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin AnalogsMolecular Pharmacology, 2005
- 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5European Journal of Nuclear Medicine and Molecular Imaging, 2004
- Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide ScintigraphyJournal of Clinical Endocrinology & Metabolism, 2003
- DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and TherapyEndocrine Reviews, 2003
- True Positive Somatostatin Receptor Scintigraphy in Primary Breast Cancer Correlates with Expression of sst2A and sst5Breast Cancer Research and Treatment, 2002
- In Vivo Internalization of the Somatostatin sst2A Receptor in Rat Brain: Evidence for Translocation of Cell-Surface Receptors into the Endosomal Recycling PathwayMolecular and Cellular Neuroscience, 2001
- Molecular Pharmacology of Somatostatin‐receptor SubtypesAnnals of the New York Academy of Sciences, 1994
- Imaging of renal cell cancer with radiolabeled octreotideNuclear Medicine Communications, 1993
- Nuclear location of hormone-free estrogen receptors by monoclonal antibodies could be a tissue-fixation dependent artifactSteroids, 1988